ORKA Oruka Therapeutics, Inc. stock chart & analysis
Conviction 0HealthcareScan · Fri, Nov 6, 2026Oruka Therapeutics, Inc. (ORKA) closed at $102.86 (+7.12%) on Nov 6, 2026. Price is above its 50-day and above its 200-day moving average. RSI(14) 67, RS Rating 99, -11.1% from its 52-week high, +239.0% year to date. Sector: Healthcare · Pharmaceutical Preparations.
Financials as of Tue, Jun 30, 2026 · quarterly.
ORKA technical analysis
Trend
ORKA is in an uptrend: price is above the 50-day, which is above the 200-day moving average. It closed 16.5% above the 50-day ($88.21) and 45.0% above the 200-day ($70.86). ADX(14) at 31 points to a strong, established trend. It meets 8 of 8 trend-template criteria.
Momentum
RSI(14) is 67, in the bullish half of its range. The MACD histogram is positive. Its RS Rating of 99 puts its weighted 12-month performance ahead of about 99% of the US market.
Volume and volatility
Volume on the latest session ran 0.6× its 20-day average. It trades about $73.4M a day on average. ATR(14) is $5.29, 5.1% of price — its typical daily range. On-balance volume is trending up.
Key levels
The chart pattern's support is $73.17 and its resistance $92.40. The 52-week range is $25.23 to $115.52; price is 11.1% below the high and 307.2% above the low. The VWAP anchored at the 52-week high is $89.97, below price.
Performance
ORKA returned +6.1% (1 week), +33.0% (1 month), -2.3% (3 months), +59.1% (6 months), +276.2% (1 year), +239.0% (year to date).
About Oruka Therapeutics, Inc.
Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.
Pharmaceutical Preparations · Listed 2024 · 68 employees
Insider activity
SEC Form 4 transactions in ORKA · open-market 6 sells
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Klein Lawrence Otto Chief Executive Officer · Common Stock · 2026-11-02 | Sell | 6.47K | $613K | 2026-11-02 | 2026-11-02 |
Klein Lawrence Otto Chief Executive Officer · Common Stock · 2026-11-02 | Exercise | 25K | $195K | 2026-11-02 | 2026-11-02 |
Klein Lawrence Otto Chief Executive Officer · Common Stock · 2026-11-02 | Sell | 15.04K | $1.4M | 2026-11-02 | 2026-11-02 |
Klein Lawrence Otto Chief Executive Officer · Common Stock · 2026-11-02 | Sell | 2.44K | $236K | 2026-11-02 | 2026-11-02 |
Klein Lawrence Otto Chief Executive Officer · Common Stock · 2026-11-02 | Sell | 756 | $74K | 2026-11-02 | 2026-11-02 |
Klein Lawrence Otto Chief Executive Officer · Common Stock · 2026-11-02 | Sell | 300 | $30K | 2026-11-02 | 2026-11-02 |
Klein Lawrence Otto Chief Executive Officer · Employee Warrant (right to buy) · 2026-11-02 | Exercise | 25K | — | 2026-11-02 | 2026-11-02 |
Goncalves Joana Chief Medical Officer · Common Stock · 2026-10-15 | Exercise | 3.5K | $24K | 2026-10-15 | 2026-10-15 |
Goncalves Joana Chief Medical Officer · Common Stock · 2026-10-15 | Exercise | 3.5K | $27K | 2026-10-15 | 2026-10-15 |
Goncalves Joana Chief Medical Officer · Common Stock · 2026-10-15 | Sell | 2.85K | $211K | 2026-10-15 | 2026-10-15 |
SEC filings
EDGAR filings in ORKA · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.
Start free — 7-day trial, no card →Free daily signals by email. Top 3 setups per lane after every close. No account needed.
Unsubscribe anytime · Privacy
Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.